Zacks Investment Research cut shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a buy rating to a hold rating in a research report sent to investors on Monday morning.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
ATNM has been the subject of a number of other research reports. Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals and gave the company a buy rating in a report on Tuesday, December 12th. B. Riley assumed coverage on Actinium Pharmaceuticals in a report on Wednesday, December 6th. They set a buy rating and a $2.75 price objective for the company. Roth Capital restated a buy rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Finally, HC Wainwright restated a buy rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, October 23rd. Five equities research analysts have rated the stock with a buy rating, Actinium Pharmaceuticals has an average rating of Buy and an average target price of $3.75.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.